Targeting mTORC2 in lung squamous cell carcinoma improves anti-tumor immunity through the PSGL-1-VISTA axis



Summary

Targeting mTORC2 in lung squamous cell carcinoma (LUSC) enhances anti-tumor immunity by modulating the PSGL-1-VISTA pathway. Specifically, mTORC2 inhibition increases PSGL-1 expression on LUSC cells, making them more susceptible to VISTA-mediated suppression by immune cells. Blocking VISTA, or its interaction with PSGL-1, restores T cell activity and improves anti-tumor responses. This suggests that combining mTORC2 inhibitors with VISTA blockade could be a promising therapeutic strategy for LUSC, leveraging the enhanced PSGL-1 expression on tumor cells to boost anti-tumor immunity and overcome VISTA-mediated immunosuppression.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!